Pulmonary pharmacology and therapeutics

Pulmonary pharmacology and therapeutics

COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
Andreas Renner, Katharina Marth, Karin Patocka, Marco Idzko, Wolfgang Pohl

ERJ Open Research Oct 2020, 6 (4) 00457-2020; DOI: 10.1183/23120541.00457-2020
Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study
Silke van Koningsbruggen-Rietschel, Jane C. Davies, Tacjana Pressler, Rainald Fischer, Gordon MacGregor, Scott H. Donaldson, Knut Smerud, Nils Meland, Jann Mortensen, Marie Ø. Fosbøl, Damian G. Downey, Astrid H. Myrset, Hugo Flaten, Philip D. Rye

ERJ Open Research Oct 2020, 6 (4) 00132-2020; DOI: 10.1183/23120541.00132-2020
The use of β₂-adrenoreceptor agonists in viral bronchiolitis: scientific rationale beyond evidence-based guidelines
Gustavo Nino, Carlos E. Rodríguez-Martínez, Jose A. Castro-Rodriguez

ERJ Open Research Oct 2020, 6 (4) 00135-2020; DOI: 10.1183/23120541.00135-2020
Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space
Sarah Orfanos, Ibrahim El Husseini, Thomas Nahass, Jared Radbel, Sabiha Hussain

ERJ Open Research Oct 2020, 6 (4) 00455-2020; DOI: 10.1183/23120541.00455-2020
Response to mepolizumab treatment is sustained across 4-weekly dosing periods
Ian D. Pavord, Eugene R. Bleecker, Roland Buhl, Pascal Chanez, Elisabeth H. Bel, Peter Howarth, Daniel J. Bratton, Frank C. Albers, Steven Yancey

ERJ Open Research Jul 2020, 6 (3) 00068-2020; DOI: 10.1183/23120541.00068-2020
Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design
Tim Harrison, Ian D. Pavord, James D. Chalmers, Glenn Whelan, Malin Fagerås, Annika Rutgersson, Laura Belton, Shahid Siddiqui, Per Gustafson

ERJ Open Research Apr 2020, 6 (2) 00333-2019; DOI: 10.1183/23120541.00333-2019
Doxycycline for exacerbations of chronic obstructive pulmonary disease in outpatients: who benefits?
Patricia van Velzen, Gerben ter Riet, Paul Brinkman, Peter J. Sterk, Jan M. Prins

ERJ Open Research Apr 2020, 6 (2) 00099-2020; DOI: 10.1183/23120541.00099-2020
Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
Nicola A. Hanania, Alberto Papi, Antonio Anzueto, Fernando J. Martinez, Kimberly A. Rossman, Christy S. Cappelletti, Elizabeth A. Duncan, Jack S. Nyberg, Paul M. Dorinsky

ERJ Open Research Apr 2020, 6 (2) 00187-2019; DOI: 10.1183/23120541.00187-2019
Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
Katherine B. Hisert, Timothy P. Birkland, Kelly Q. Schoenfelt, Matthew E. Long, Brenda Grogan, Suzanne Carter, W. Conrad Liles, Edward F. McKone, Lev Becker, Anne M. Manicone

ERJ Open Research Apr 2020, 6 (2) 00318-2019; DOI: 10.1183/23120541.00318-2019
Enoximone in status asthmaticus
Oscar Schulz, Olaf Wiesner, Tobias Welte, Benjamin-Alexander Bollmann, Hendrik Suhling, Marius M. Hoeper, Markus Busch

ERJ Open Research Jan 2020, 6 (1) 00367-2019; DOI: 10.1183/23120541.00367-2019

Main menu

User menu

Search

Pulmonary pharmacology and therapeutics

Pages

Contact us